Elevated Eosinophils in Chronic Obstructive Pulmonary Disease (COPD) - Possible Implications?

Elevated Eosinophils in Chronic Obstructive Pulmonary Disease (COPD) - Possible Implications?

High Eosinophil Counts in COPD Patients Linked to Severe Disease and Frequent Exacerbations

Chronic Obstructive Pulmonary Disease (COPD) is often associated with eosinophilic inflammation, a condition characterised by an accumulation of eosinophils in the lung tissues. Around 50% of people with COPD have evidence of eosinophilic inflammation, a number that increases during COPD exacerbations.

In a study involving nearly 40,000 people with COPD, 34.9% had blood eosinophil counts of ≥340 cells/μL compared with 25.8% of people without COPD. In the WISDOM trial, 53% of COPD participants had ≥150 cells/μL, 20% had ≥300 cells/μL, and 11% had ≥400 cells/μL.

This eosinophilic inflammation in COPD is linked to worse clinical outcomes, including more frequent and severe exacerbations, especially in patients with a history of recurrent exacerbations. Elevated eosinophil counts (e.g., ≥340-350 cells/µL) correlate with a 1.7- to 2.4-fold higher risk of moderate to severe exacerbations, accelerating disease progression and increasing morbidity and mortality.

The cornerstone of COPD treatment remains inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), and long-acting muscarinic antagonists (LAMA). ICS may be more beneficial in patients with elevated eosinophils to reduce exacerbations. Anti-IL-5 monoclonal antibodies, such as mepolizumab, are under investigation for targeting eosinophilic inflammation. The MATINEE trial showed that mepolizumab can reduce exacerbations in eosinophilic COPD patients, especially those with frequent exacerbations.

Treatment decisions for COPD with eosinophilia should be made on a case-by-case basis, considering the person's symptoms, history, and other factors influencing treatment response. It is unclear if ICS therapy is beneficial in people with COPD and low eosinophil counts with no pneumonia history.

The normal range for eosinophil blood levels is typically between 0 and 500 cells per microliter (cells/μL). The GOLD guidelines use an eosinophilia cutoff of >300 cells/μL as a predictor of ICS effects. Higher levels of eosinophils in COPD are associated with an increased risk of future exacerbations, higher early mortality, and shorter duration of mechanical ventilation.

Mepolizumab treatment may provide some benefit to people with eosinophilic COPD, and people with eosinophilia have a lower rate of ICU admission in severe COPD exacerbations. However, regulatory agencies like the FDA have been cautious, requiring more data before approving these biologics for COPD.

In severe exacerbations of COPD requiring hospitalization, people with eosinophilia respond faster to treatment with shorter hospital stays. ICS treatment can be a valuable part of therapy for someone with COPD who has a high eosinophil count and no history of pneumonia. The exact mechanism by which COPD causes high eosinophil levels is not fully understood. Further research is ongoing to refine patient selection and expand treatment options.

1. The accumulation of eosinophils in the lung tissues of COPD patients is a characteristic of eosinophilic inflammation, a condition associated with severe disease and frequent exacerbations.
2. In a study with over 40,000 COPD patients, about 35% had high eosinophil counts compared to those without COPD.
3. Eosinophilic inflammation in COPD is linked to increased risk, accelerated disease progression, and higher mortality due to more frequent and severe exacerbations.
4. Inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), and long-acting muscarinic antagonists (LAMA) are the cornerstone of COPD treatment, and ICS may be more beneficial in patients with elevated eosinophil counts to reduce exacerbations.
5. Anti-IL-5 monoclonal antibodies like mepolizumab are under investigation for targeting eosinophilic inflammation and have shown to reduce exacerbations in eosinophilic COPD patients.
6. Treatment for COPD with eosinophilia should be personalized based on symptoms, history, and other factors, as it remains unclear if ICS therapy benefits those with low eosinophil counts and no pneumonia history.
7. Elevated eosinophil counts in COPD are linked to increased risk of future exacerbations, higher early mortality, and shorter duration of mechanical ventilation. In severe exacerbations, people with eosinophilia respond faster to treatment and have shorter hospital stays.

Read also: